Research progress of HPV therapeutic vaccine
10.3760/cma.j.issn.0253-9624.2018.05.017
- VernacularTitle: HPV治疗性疫苗研究进展
- Author:
Shuang ZHAO
1
;
Fanghui ZHAO
Author Information
1. Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Publication Type:Review
- Keywords:
Vaccines;
Human papillomavirus;
Cervical cancer;
Therapeutic vaccines
- From:
Chinese Journal of Preventive Medicine
2018;52(5):556-560
- CountryChina
- Language:Chinese
-
Abstract:
Bivalent and quadrivalent HPV vaccine have been approved by CFDA successively in China. However, currently available prophylactic vaccines have no therapeutic effect for established infection or disease. In recent years, based on the application of genomics and proteomics for interpretation of tumor antigen, animal experiments and clinical trials of vaccines aiming at a wide variety of antigens have been conducted. In this review, we summarize about the preclinical and clinical research status of HPV therapeutic vaccine and find that the efficacy of HPV therapeutic vaccine alone or combined with other conventional cancer treatment is satisfying, which has potential clinical application value. As the further research of tumor immune regulation and optimization of strategies for the HPV therapeutic vaccine, the vaccine will play an important role in improving the quality of life in cancer patients and eventually become widely used in clinical practice.
